Cited In for PMID: 35738799

Year	Number of Results
2022	3
2023	11
2024	24
2025	8

1

PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.

Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X, Martinez C, Dorff TB, Forman SJ, Priceman SJ. Yamaguchi Y, et al. J Immunother Cancer. 2022 Jun;10(6):e004400. doi: 10.1136/jitc-2021-004400. J Immunother Cancer. 2022. PMID: 35738799 Free PMC article.

2

Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.

Noraldeen SAM, Rasulova I, Lalitha R, Hussin F, Alsaab HO, Alawadi AH, Alsaalamy A, Sayyid NH, Alkhafaji AT, Mustafa YF, Shayan SK. Noraldeen SAM, et al. Med Oncol. 2023 Oct 1;40(11):313. doi: 10.1007/s12032-023-02191-7. Med Oncol. 2023. PMID: 37779152 Review.

3

Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers.

Zhang K, Mi Y, Zhang B, Xue X, Ding Y, Ma J, Yuan E, Zhao X, Zheng P. Zhang K, et al. Oncogene. 2025 Jun;44(20):1463-1474. doi: 10.1038/s41388-025-03322-2. Epub 2025 Mar 1. Oncogene. 2025. PMID: 40025231

4

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.

Wang Z, Zhou L, Wu X. Wang Z, et al. Oncol Res. 2024 Aug 23;32(9):1479-1516. doi: 10.32604/or.2024.048564. eCollection 2024. Oncol Res. 2024. PMID: 39220130 Free PMC article. Review.

5

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.

Tian H, Cao J, Li B, Nice EC, Mao H, Zhang Y, Huang C. Tian H, et al. Bone Res. 2023 Feb 27;11(1):11. doi: 10.1038/s41413-023-00246-z. Bone Res. 2023. PMID: 36849442 Free PMC article. Review.

6

Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.

Zheng F, Zhang S, Chang AE, Moon JJ, Wicha MS, Wang SX, Chen J, Liu J, Cheng F, Li Q. Zheng F, et al. Int J Biol Sci. 2025 Feb 10;21(4):1819-1836. doi: 10.7150/ijbs.101025. eCollection 2025. Int J Biol Sci. 2025. PMID: 39990669 Free PMC article. Review.

7

GAS-Luc2 Reporter Cell Lines for Immune Checkpoint Drug Screening in Solid Tumors.

Chang H, Foulke JG, Chen L, Tian F, Gu Z. Chang H, et al. Cancers (Basel). 2024 May 22;16(11):1965. doi: 10.3390/cancers16111965. Cancers (Basel). 2024. PMID: 38893085 Free PMC article.

8

Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.

Chen J, Zhu T, Jiang G, Zeng Q, Li Z, Huang X. Chen J, et al. Mol Cancer. 2023 Aug 10;22(1):131. doi: 10.1186/s12943-023-01830-x. Mol Cancer. 2023. PMID: 37563723 Free PMC article.

9

CAR-armored-cell therapy in solid tumor treatment.

Liu Y, Xiao L, Yang M, Chen X, Liu H, Wang Q, Guo M, Luo J. Liu Y, et al. J Transl Med. 2024 Nov 28;22(1):1076. doi: 10.1186/s12967-024-05903-3. J Transl Med. 2024. PMID: 39609705 Free PMC article. Review.

10

Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells.

Kennewick KT, Yamaguchi Y, Gibson J, Gerdts EA, Jeang B, Tilakawardane D, Murad JP, Chang WC, Wright SL, Thiel MS, Forman SJ, Stern LA, Priceman SJ. Kennewick KT, et al. Mol Ther Oncol. 2024 Mar 2;32(2):200789. doi: 10.1016/j.omton.2024.200789. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38939825 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 35738799

43 results

Results by year